Moxifloxacin Olikla (Moxifloxacin Hydrochloride)

• Moxifloxacin Olikla is a fluoroquinolone antibiotic used to treat bacterial infections of the eye.
• Bacterial conjunctivitis: reduces bacterial load and accelerates resolution of redness, discharge and irritation.
• Bacterial keratitis: eradicates causative organisms to prevent corneal damage and preserve vision.
• Other bacterial ocular infections: effective against susceptible Gram‑positive and Gram‑negative bacteria causing eyelid or surface infections.

• Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription and repair. By binding to the quinolone‑resistance‑determining region of these enzymes, it prevents supercoiling of DNA, leading to bacterial cell death and providing bactericidal activity against a wide range of ocular pathogens.

Topical ocular administration of moxifloxacin may be associated with local and systemic adverse reactions.

Common Side Effects

• Transient eye irritation: mild burning or stinging upon instillation.
• Redness: temporary conjunctival hyperemia.
• Blurred vision: short‑lasting visual disturbance.
• Tearing: increased lacrimation.
• Foreign body sensation: feeling of grit in the eye.

Serious or Rare Side Effects

• Corneal ulceration: development of a non‑healing corneal lesion.
• Severe allergic reaction: eyelid edema, hives or anaphylaxis.
• Vision loss: rapid decrease in visual acuity.
• Tendon rupture: rare systemic tendon injury.

• Before prescribing Moxifloxacin Olikla, consider the following safety measures.
• Allergy assessment: avoid use in patients with known hypersensitivity to fluoroquinolones.
• Contact lens wearers: discontinue lenses before and after treatment to reduce risk of keratitis.
• Pregnancy and lactation: use only if clearly needed, as safety data are limited.
• Concurrent ocular surgery: postpone elective procedures until therapy is completed.
• Systemic fluoroquinolone use: monitor for additive toxicity.
• Store at room temperature: keep in original container, protect from light and moisture.

Moxifloxacin Olikla may interact with other ophthalmic or systemic agents.

Major Interactions (Avoid)

• Systemic fluoroquinolones: increased risk of additive QT prolongation.
• Corticosteroid eye drops: may mask signs of infection.
• Anticholinergic agents: potential reduction in ocular surface lubrication.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory eye drops: may affect drug absorption.
• Herbal supplements containing quinine: possible competitive inhibition.
• High‑dose vitamin C: may alter ocular pH affecting drug stability.